Mirum Pharmaceuticals Net Income Over Time
| MIRM Stock | USD 103.14 0.04 0.04% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Mirum Pharmaceuticals Performance and Mirum Pharmaceuticals Correlation. Will Biotechnology sector continue expanding? Could Mirum diversify its offerings? Factors like these will boost the valuation of Mirum Pharmaceuticals. Expected growth trajectory for Mirum significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mirum Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.84) | Revenue Per Share | Quarterly Revenue Growth 0.472 | Return On Assets | Return On Equity |
Understanding Mirum Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Mirum's accounting equity. The concept of intrinsic value - what Mirum Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Mirum Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Mirum Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mirum Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Mirum Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Mirum Pharmaceuticals and related stocks such as Belite Bio ADR, Soleno Therapeutics, and Ligand Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BLTE | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (9.7 M) | (12.6 M) | (31.6 M) | (36.1 M) | (32.5 M) | (30.9 M) |
| SLNO | (6.5 M) | (6.5 M) | (6.5 M) | (3.7 M) | (13.9 M) | (15.9 M) | (12.1 M) | (15.7 M) | (13.3 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (39 M) | (175.8 M) | (158.3 M) | (150.4 M) |
| LGND | (27.1 M) | 10.2 M | (527 K) | 11.4 M | 12 M | 257.3 M | (1.6 M) | 12.6 M | 143.3 M | 629.3 M | (3 M) | 57.1 M | (33.4 M) | 52.2 M | (4 M) | (4.6 M) | (4.4 M) |
| ADMA | (29.7 M) | (26.5 K) | (7.3 M) | (15.5 M) | (16.8 M) | (18 M) | (19.5 M) | (43.8 M) | (65.7 M) | (48.3 M) | (75.7 M) | (71.6 M) | (65.9 M) | (28.2 M) | 197.7 M | 227.3 M | 238.7 M |
| PRAX | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (35.5 M) | (61.8 M) | (166.9 M) | (213.1 M) | (123.3 M) | (182.8 M) | (164.5 M) | (172.8 M) |
| ACAD | (10.2 M) | (22.8 M) | (20.8 M) | (37.9 M) | (92.5 M) | (164.4 M) | (271.4 M) | (289.4 M) | (245.2 M) | (235.3 M) | (281.6 M) | (167.9 M) | (216 M) | (61.3 M) | 226.5 M | 203.8 M | 214 M |
| DYN | 264 M | (1.6 B) | 87 M | (356 M) | (67 M) | 50 M | (1.2 B) | 76 M | (4.8 M) | (13.5 M) | (58.7 M) | (149.3 M) | (165.2 M) | (235.9 M) | (317.4 M) | (365 M) | (383.3 M) |
| TVTX | (18.3 K) | (14.8 K) | (30.3 M) | (33.8 M) | (110.9 M) | 117.2 M | (47.9 M) | (59.7 M) | (102.7 M) | (146.4 M) | (169.4 M) | (180.1 M) | (278.5 M) | (111.4 M) | (321.5 M) | (289.4 M) | (274.9 M) |
| RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (575 M) | (546.2 M) |
| TLX | (289 K) | (2.5 M) | (2.5 M) | (2.5 M) | 5.4 M | (132 K) | (44 K) | (6.4 M) | (13.8 M) | (27.9 M) | (44.9 M) | (80.5 M) | (104.1 M) | 5.2 M | 49.9 M | 44.9 M | 47.2 M |
Mirum Pharmaceuticals and related stocks such as Belite Bio ADR, Soleno Therapeutics, and Ligand Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Mirum Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Mirum Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Mirum Pharmaceuticals | MIRM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 950 Tower Lane, |
| Exchange | NASDAQ Exchange |
USD 103.14
Check out Mirum Pharmaceuticals Performance and Mirum Pharmaceuticals Correlation. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Mirum Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.